Amylyx Pharmaceuticals, Inc.
AMLX
$14.64
$0.432.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.03% | -15.42% | 4.37% | 48.36% | -0.01% |
| Total Depreciation and Amortization | -14.89% | -9.62% | -2.50% | -27.60% | 6.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.24% | 18.73% | 0.96% | -87.76% | 184.18% |
| Change in Net Operating Assets | -119.42% | 208.26% | 65.54% | -151.99% | -21.87% |
| Cash from Operations | -20.28% | 36.60% | 32.51% | -41.95% | 37.56% |
| Capital Expenditure | -41.18% | -54.55% | 99.97% | -190,747.37% | 121.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -77.14% | 152.72% | -143.13% | 160.85% | 234.38% |
| Cash from Investing | -77.23% | 152.67% | -167.19% | 67.41% | 234.03% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,593.06% | -92.58% | 555.41% | -69.86% | 944.68% |
| Repurchase of Common Stock | -2,000.97% | 88.36% | -2,228.95% | 90.75% | -1,955.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 618,183.87% | -100.05% | 59,592.73% | 37.50% | 196.30% |
| Foreign Exchange rate Adjustments | -75.16% | 208.63% | 137.52% | -322.46% | 705.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10,035.90% | 90.48% | -417.15% | 327.93% | 97.45% |